The Lancet: Targeted drug doubles progression free survival in Hodgkin lymphoma
(Press-News.org) A phase 3 trial of brentuximab vedotin (BV), the first new drug for Hodgkin lymphoma in over 30 years, shows that adults with hard-to-treat Hodgkin lymphoma given BV immediately after stem cell transplant survived without the disease progressing for twice as long as those given placebo (43 months vs 24 months).
The findings, published in The Lancet, are potentially practice changing for this young cancer population who have exhausted other treatment options and for whom prognosis is poor.
"No medication available today has had such dramatic results in patients with hard-to-treat Hodgkin lymphoma"*, says lead author Craig Moskowitz, a Professor of Medicine at Memorial Sloan Kettering Cancer Center, New York, USA.
Hodgkin lymphoma is the most common blood cancer in young adults aged between 15 and 35 years. Most patients are cured with chemotherapy or radiotherapy. However, for patients who relapse, or do not respond to initial therapy, the treatment of choice is usually a combination of high-dose chemotherapy and autologous stem cell transplant (ASCT)--a procedure that uses healthy stem cells from the patient to replace those lost to disease or chemotherapy. While about 50% of patients who undergo this procedure are cured, for the other half treatment is palliative.
BV is an antibody attached to a powerful chemotherapy drug that seeks out cancer cells by targeting the CD30 protein on Hodgkin lymphoma cells. BV sticks to the CD30 protein and delivers chemotherapy directly into the cancer cell to kill it. Recently, BV has been approved for relapsed or refractory Hodgkin lymphoma in 50 countries.
In the AETHERA phase 3 trial, Moskowitz and colleagues aimed to establish whether early treatment with BV after ASCT could prevent disease progression. They randomly assigned 329 patients with Hodgkin lymphoma aged 18 or older who were at high risk of relapse or progression after ASCT to 16 cycles of BV infusions once every 3 weeks or placebo.
At 2 years follow up, the cancer had not progressed at all in 65% of BV patients compared with 45% in the placebo group. "Nearly all of these patients who are progression free at 2 years are likely to be cured since relapse 2 years after a transplant is unlikely"*, explains Dr Moskowitz.
BV was generally well tolerated. The most common side effects were peripheral neuropathy (numbness or pain in the extremities due to nerve damage; 67% BV vs 13% placebo) and neutropenia (low white blood count; 35% vs 12%).
According to Dr Moskowitz, "The bottom line is that BV is a very effective drug in poor risk Hodgkin lymphoma and it spares patients from the harmful effects of further traditional chemotherapy by breaking down inside the cell resulting in less toxicity."*
Writing in a linked Comment, Professor Andreas Engert from the University Hospital of Cologne in Germany discusses how best to define which patients are at high risk of relapse and should be treated with BV. He writes, "AETHERA is a positive study establishing a promising new treatment approach for patients with Hodgkin's lymphoma at high risk for relapse. However, with a progression-free survival of about 50% at 24 months in the placebo group, whether this patient population is indeed high risk could be debated...An international consortium is currently reassessing the effect of risk factors in patients with relapsed Hodgkin's lymphoma to define a high-risk patient population in need of consolidation treatment. We look forward to a better definition of patients with relapsed Hodgkin's lymphoma who should receive consolidation treatment with brentuximab vedotin.
Notes to Editors:
This study was funded by Seattle Genetics, Inc and Takeda Pharmaceuticals International Co
*Quotes direct from author and cannot be found in text of Article.
ELSE PRESS RELEASES FROM THIS DATE:
EAST LANSING, Mich. - Malaria kills a child every minute. While medical researchers have successfully developed effective drugs to kill the malaria parasite, efforts to treat the effects of the disease have not been as successful. But that soon may change.
In a groundbreaking study published in the New England Journal of Medicine, Michigan State University's Dr. Terrie Taylor and her team discovered what causes death in children with cerebral malaria, the deadliest form of the disease.
"We discovered that some children with cerebral malaria develop massively swollen ...
Drug companies have made incremental improvements that kept insulin under patent for more than 90 years.
Insulin can cost $120 to $400 per month for patients with no prescription drug coverage.
Many patients with diabetes have lapses in medication that can lead to serious complications requiring hospitalization.
A generic version of insulin, the lifesaving diabetes drug used by 6 million people in the United States, has never been available in this country because drug companies have made incremental improvements that kept insulin under patent from ...
Cardiometabolic risk factors, such as high blood pressure and elevated blood sugar, appear to have a bigger effect than obesity on hardening arteries early among Mexican-Americans, according to research in the Journal of the American Heart Association.
"Even among non-obese Mexican-Americans, there is already a high prevalence of clustering of cardiometabolic risk factors," said Susan T. Laing, M.D., M.Sc., lead study author and professor of cardiovascular medicine at the University of Texas Health Science Center at Houston.
"We will begin to see the impact of the high ...
MINNEAPOLIS - Researchers have developed a new scoring system to help determine which elderly people may be at a higher risk of developing the memory and thinking problems that can lead to dementia, according to a new study published in the March 18, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.
"Our goal is to identify memory issues at the earliest possible stages," said study author Ronald C. Petersen, MD, PhD, of Mayo Clinic in Rochester, Minn., and a member of the American Academy of Neurology. "Understanding what ...
ROCHESTER, Minn - Researchers at Mayo Clinic developed a new scoring system to help determine which elderly people may be at a higher risk of developing the memory and thinking problems that can lead to dementia. The study is published in the March 18, 2015, online issue of Neurology®, the medical journal of the American Academy of Neurology.
"Our goal is to identify people who are at the highest risk for dementia as early as possible" said study author Ronald Petersen, M.D., Ph.D., Chester and Debbie Cadieux Director of the Mayo Clinic Alzheimer's Disease Research ...
Preserving isolated patches of habitat isn't enough to save species such as Bachman's Sparrow (Peucaea aestivalis) that depend on longleaf pine; habitat connectivity at the landscape level is also crucial. That is the message of a new paper by Paul Taillie, M. Nils Peterson, and Christopher Moorman of North Carolina State University, published this week in The Condor: Ornithological Applications.
In the past, fire-dependent longleaf pine forests covered vast, unbroken areas of the southeastern U.S., and Bachman's Sparrows and other species adapted to live in this expansive ...
The TRMM satellite revealed that Tropical Cyclone Nathan had powerful thunderstorms known as "hot towers" near its center which are indicative of a strengthening storm.
Cyclone Nathan is located in the Coral Sea off Australia's Queensland coast. Nathan formed on March 10 near the Queensland coast triggering warnings there before moving east. Once out at sea, Nathan made a loop and headed back to Queensland.
On March 18, Nathan was nearing the Cape York Peninsula of Queensland. As a result warnings were in effect from Cape Melville to Innisfail, extending inland to Laura. ...
Modern life, with its preponderance of inadequate exposure to natural light during the day and overexposure to artificial light at night, is not conducive to the body's natural sleep/wake cycle.
It's an emerging topic in health, one that UConn Health (University of Connecticut, Farmington, Conn.) cancer epidemiologist Richard Stevens has been studying for three decades.
"It's become clear that typical lighting is affecting our physiology," Stevens says. "But lighting can be improved. We're learning that better lighting can reduce these physiological effects. By that ...
CORAL GABLES, Fla. (March 18, 2015) -- Come spring break, college students from all over the country travel to warmer climates for time off from school and to escape the cold weather. However, it's not all fun in the sun. At popular spring break destinations, fatalities from car crashes are significantly higher during the spring break weeks compared to other times of the year, according to a recent study published in the journal Economic Inquiry.
"We found that between the last week of February and the first week of April, a significantly greater number of traffic fatalities ...
There's a carbon showdown brewing in the Arctic as Earth's climate changes. On one side, thawing permafrost could release enormous amounts of long-frozen carbon into the atmosphere. On the opposing side, as high-latitude regions warm, plants will grow more quickly, which means they'll take in more carbon from the atmosphere.
Whichever side wins will have a big impact on the carbon cycle and the planet's climate. If the balance tips in favor of permafrost-released carbon, climate change could accelerate. If the balance tips in favor of carbon-consuming plants, climate ...
LAST 30 PRESS RELEASES:
[Press-News.org] The Lancet: Targeted drug doubles progression free survival in Hodgkin lymphoma